(NASDAQ: EWTX) Edgewise Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.01%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.56%.
Edgewise Therapeutics's earnings in 2026 is -$197,222,000.On average, 16 Wall Street analysts forecast EWTX's earnings for 2026 to be $142,694,965, with the lowest EWTX earnings forecast at -$257,565,552, and the highest EWTX earnings forecast at $1,217,886,703. On average, 15 Wall Street analysts forecast EWTX's earnings for 2027 to be -$205,859,127, with the lowest EWTX earnings forecast at -$366,126,240, and the highest EWTX earnings forecast at -$53,596,138.
In 2028, EWTX is forecast to generate -$195,769,803 in earnings, with the lowest earnings forecast at -$299,074,050 and the highest earnings forecast at -$20,526,180.